Physician profile
Peter B Burns
NPI 1891727533
$5,078.02
in general payments reported to CMS, 2019-2025
12 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $463 · 2022: $522 · 2023: $965 · 2024: $1,456 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,970 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,970.37 |
| Education | $123.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,179.24 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $729.97 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $598.95 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $561.02 | 2022-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $452.97 | 2022-2024 | Caplyta |
| Abbvie INC. | $373.56 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $347.67 | 2023-2025 | Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $235.75 | 2023 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $199.89 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $184.74 | 2024-2025 | Fanapt, Hetlioz |
| Eisai INC. | $121.84 | 2025 | |
| Lundbeck LLC | $92.42 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.